Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UPP1 | Q16831 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37272 | 0.87 | PNP (0.54) | UPP1P2RY1ADORA1ADORA3ADORA2A | |
| SCHEMBL37437 | 0.87 | PNP (0.54) | UPP1P2RY1ADORA1ADORA3ADORA2A | |
| SCHEMBL1219170 | 0.87 | PNP (0.54) | UPP1P2RY1ADORA1ADORA3ADORA2A | |
| SCHEMBL9393705 | 0.84 | LMNA (0.49) | UPP1P2RY1POLB | |
| SCHEMBL7200818 | 0.84 | LMNA (0.49) | UPP1P2RY1POLB | |
| SCHEMBL6559404 | 0.84 | LMNA (0.49) | UPP1P2RY1POLB | |
| SCHEMBL6559406 | 0.84 | LMNA (0.49) | UPP1P2RY1POLB | |
| SCHEMBL7516274 | 0.82 | PNP (0.52) | UPP1P2RY1ADORA1ADORA3ADORA2A | |
| SCHEMBL14326921 | 0.82 | POLB (0.46) | UPP1P2RY1ADORA1ADORA3POLB | |
| SCHEMBL15031043 | 0.82 | LMNA (0.49) | UPP1P2RY1ADORA1ADORA3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467391-B1 | PROCESS FOR THE PREPARATION OF CLADRIBINE | SCINOPHARM KUNSHAN BIOCHEMICAL TECHNOLOGY CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| EP-2891660-A1 | Process for the preparation of cladribine | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-8338586-B2 | Process of making cladribine | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) | 2012-12-25 | — | — | US | disclosed |
| US-20120197010-A1 | PROCESS OF MAKING CLADRIBINE | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) | 2012-08-02 | — | — | US | disclosed |
| US-8232387-B2 | Process for the preparation of cladribine | SCINOPHARM TAIWAN, LTD. (TW) | 2012-07-31 | — | — | US | disclosed |
| EP-2467391-A1 | PROCESS FOR THE PREPARATION OF CLADRIBINE | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. (CN) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020298-A1 | PROCESS FOR THE PREPARATION OF CLADRIBINE | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) | 2011-02-24 | — | — | WO | disclosed |
| US-20110046363-A1 | Process for the Preparation of Cladribine | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197010-A1 | PROCESS OF MAKING CLADRIBINE | PNP, CPSF1, NSUN2 | UPP1 26/4885P2RY1 1626/4885ADORA1 740/4885 |
| US-20110046363-A1 | Process for the Preparation of Cladribine | ADAR, RNMT, RNGTT | UPP1 300/4885P2RY1 3488/4885ADORA1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.